Document is current
Any future updates will be listed below
-
Authors
Sharma, Divija
Ungar, Benjamin
Adalsteinsson, Jonas A.
Sigurdsson, Jon Kristinn
Sharp, Kelley
Thorsteinsdóttir, Sigrún
Rögnvaldsson, Saemundur
Þórðardóttir, Ásdís R
Viðarsson, Brynjar
Önundarson, Páll T
Agnarssond, Bjarni A
Sigurðardóttird, Margrét
Þorsteinsdóttir, Ingunn
Ólafsson, Ísleifur
Eyþórsson, Elías
Jónsson, Ásbjörn
Ólafsson, Andri
Gíslason, Gauti Kjartan
Landgren, Ola
Hulcrantz, Malin
Durie, Brian GM
Harding, Stephen
Love, Thorvardur Jon
Kristinsson, Sigurdur Yngvi
- License Information
-
More Information
Article History
Received: 12 July 2024
Revised: 15 July 2024
Accepted: 3 September 2024
First Online: 14 September 2024
Declarations
:
: BU is an employee of Mount Sinai and has received research funds (grants paid to the institution) from: Arcutis Biotherapeutics, Incyte, Rapt Therapeutics, Pfizer, and Sanofi. He is also a consultant for Arcutis Biotherapeutics, Bristol Myers Squibb, Castle Biosciences, Fresenius Kabi, Galderma, Janssen, Lilly, Pfizer, Primus Pharmaceuticals, Sanofi, and UCB. The other authors have no conflicts.
: Not applicable.
: The study protocol, all information material, biobank, and questionnaires were approved by the Icelandic National Bioethics Committee (Number 16–022, date: 2016-04-26) with approval from the Icelandic Data Protection Agency.
